Viking Therapeutics, Inc. (VKTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | - | - | - | |
| Research and development | 60,153 | 41,391 | 22,785 | |
| General and administrative | 14,421 | 14,078 | 13,771 | |
| Total operating expenses | 74,574 | 55,469 | 36,556 | |
| Loss from operations | -74,574 | -55,469 | -36,556 | |
| Realized gain on investment | - | - | 109 | |
| Realized gain on investments, net | 4 | - | - | |
| Amortization of financing costs | 24 | 24 | 24 | |
| Interest income, net | 9,033 | 9,864 | 11,531 | |
| Total other income, net | 9,013 | 9,840 | 11,616 | |
| Net loss | -65,561 | -45,629 | -24,940 | |
| Foreign currency translation gain (loss) | 24 | 9 | 2 | |
| Unrealized gain (loss) on securities | 26 | 563 | 3,902 | |
| Comprehensive loss | -65,511 | -45,057 | -21,036 | |
| Earnings per share, basic | -0.58 | -0.41 | -0.22 | |
| Earnings per share, diluted | -0.58 | -0.41 | -0.22 | |
| Weighted average number of shares outstanding, basic | 112,134,000 | 112,069,000 | 110,911,000 | |
| Weighted average number of shares outstanding, diluted | 112,134,000 | 112,069,000 | 110,911,000 | |